Transcriptional upregulation of ARS2 was independent of biological sex (Supplementary Fig. 1D,E), was associated with early effector differentiation of CD8+ T cells (Supplementary Table 2 of Kakaradov et al. [24]), and occurred following in vivo antigen stimulation of CD8+ T cells in murine bacterial, viral, and tumor models (Supplementary Fig. 1F, G, H), suggesting that ARS2 upregulation is a general feature of CD8+ T-cell activation. The gene discussed is CD8A; the disease is neoplasm.